menu
    • menu

    Company profile for ImmuneSensor Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ImmuneSensor Therapeutics is a clinical-stage biotechnology company led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of disease. Leveraging the incredible versatility and therapeutic potential of the cGAS-STING pathway, we are focused on discovering and developing novel medicines that address both cancers and a...
    ImmuneSensor Therapeutics is a clinical-stage biotechnology company led by a team of experienced biotech professionals who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of disease. Leveraging the incredible versatility and therapeutic potential of the cGAS-STING pathway, we are focused on discovering and developing novel medicines that address both cancers and autoimmune diseases. Our growing pipeline includes STING agonists, designed to elicit anticancer immunity, as well as cGAS antagonists, which work to suppress autoimmunity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmuneSensor TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2110 Research Row Suite 610 Dallas, TX 75235
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immunesensor.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmuneSensor Doses First Patient in Phase 1b IMSB-301 AGS Trial
    ImmuneSensor Doses First Patient in Phase 1b IMSB-301 AGS Trial

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237133/0/en/ImmuneSensor-Therapeutics-Doses-First-Patient-with-Aicardi-Gouti%C3%A8res-Syndrome-AGS-in-Phase-1b-Clinical-Study-of-cGAS-inhibitor-IMSB301.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    ImmuneSensor Receives Orphan Drug & Rare Disease Designations
    ImmuneSensor Receives Orphan Drug & Rare Disease Designations

    20 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/20/2984389/0/en/ImmuneSensor-Therapeutics-Receives-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-from-the-U-S-FDA-for-cGAS-Inhibitor-Drug-Candidate-IMSB301-for-the-Treatment-of-Aicardi-Gouti.html

    GLOBENEWSWIRE
    20 Nov 2024
    Share Share
    ImmuneSensor Initiates Dosing In IMSB301 Phase 1 Trial
    ImmuneSensor Initiates Dosing In IMSB301 Phase 1 Trial

    08 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/10/08/2959610/0/en/ImmuneSensor-Therapeutics-Initiates-Dosing-in-Phase-1-Clinical-Trial-of-Lead-cGAS-Inhibitor-Drug-Candidate-IMSB301.html

    GLOBENEWSWIRE
    08 Oct 2024
    Share Share
    ImmuneSensor Granted Patent for Oral cGAS Inhibitors
    ImmuneSensor Granted Patent for Oral cGAS Inhibitors

    17 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/17/2947387/0/en/ImmuneSensor-Therapeutics-Granted-New-U-S-Patent-for-its-Oral-cGAS-Inhibitors.html

    GLOBENEWSWIRE
    17 Sep 2024
    Share Share
    ImmuneSensor At UBS Virtual Biotechnology Company Symposium
    ImmuneSensor At UBS Virtual Biotechnology Company Symposium

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2947008/0/en/ImmuneSensor-Therapeutics-to-Participate-in-the-UBS-2024-Virtual-Biotechnology-Private-Company-Symposium.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    ImmuneSensor Gets Approval For Phase 1 Trial Of IMSB301 In Australia
    ImmuneSensor Gets Approval For Phase 1 Trial Of IMSB301 In Australia

    19 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/19/2932072/0/en/ImmuneSensor-Therapeutics-Receives-Clearance-from-Australian-Regulators-to-Initiate-a-First-in-Human-Phase-1-Clinical-Trial-of-cGAS-inhibitor-Drug-Candidate-IMSB301.html

    GLOBENEWSWIRE
    19 Aug 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search